The launch brings together innovative diabetes care, trusted information and reliable supply to make healthcare more accessible.
PHNOM PENH, Cambodia, 31 October 2026 — Zuellig Pharma announces the launch of Original r-DNA Semaglutide in Cambodia, expanding treatment options for adults living with type 2 diabetes with obesity. Developed by NOVO, a global leader in diabetes care for more than 100 years, the once-weekly prescription injection helps improve blood glucose control alongside diet and exercise. Through its role in introducing and distributing the medicine locally, Zuellig Pharma aims to support healthcare professionals in providing appropriate treatment and advance its purpose of making healthcare more accessible.
The launch comes as Cambodia addresses a substantial diabetes burden. The Ministry of Health reported 274,653 new type 2 diabetes cases seen at public health facilities in 2025. Beyond raised blood glucose, diabetes is associated with increased risks of heart attack, stroke and kidney failure, highlighting the importance of care that considers patients’ long-term health.
The introduction of Original r-DNA Semaglutide in Cambodia represents a practical step towards advancing healthcare accessibility. By broadening treatment options and providing healthcare professionals with reliable product information, Zuellig Pharma aims to support informed treatment decisions and facilitate access to care suited to patients’ medical needs.
Through its partnership with NOVO, Zuellig Pharma aims to expand sustainable access to innovative diabetes care in Cambodia. The collaboration reflects a shared commitment to patient-centered care and to addressing unmet healthcare needs among people living with type 2 diabetes with obesity.
A treatment option within comprehensive diabetes care
Original r-DNA Semaglutide belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. Its active ingredient, semaglutide, helps lower blood glucose by increasing insulin release and reducing glucagon release when blood glucose is high. It is injected under the skin once a week, with the dose determined by the prescribing healthcare professional.
The launch gathers a group of medical experts for presentations and a panel discussion. Blood glucose control remains essential, and so does assessing cardiovascular risk and kidney health. Early assessment and regular monitoring help us identify complications and develop a care plan that reflects each patient’s needs.
Clinical research has also examined semaglutide’s effects beyond blood glucose control. In SUSTAIN-6, adults with type 2 diabetes at high cardiovascular risk experienced fewer events in the combined outcome of cardiovascular death, non-fatal heart attack or non-fatal stroke with semaglutide than with placebo.[1] In FLOW, adults with type 2 diabetes and chronic kidney disease had a lower risk of a combined outcome comprising kidney failure, substantial loss of kidney function, or death from kidney-related or cardiovascular causes. These findings concern the populations studied; prescribing in Cambodia must follow locally approved product information.
Patients should consult a healthcare professional about suitability and use the medicine only as prescribed. Medication should form part of care that includes healthy eating, physical activity and regular screening for complications.
Making healthcare more accessible through responsible distribution
Zuellig Pharma works with multinational pharmaceutical companies, healthcare professionals, medical associations, and public and private healthcare institutions to expand access to innovative treatments. Its distribution network and cold-chain capabilities support reliable supply through authorised channels, while appropriate storage and handling help maintain product quality. These activities reflect the company’s commitment to quality and integrity across the healthcare system.
Access extends beyond product availability. Alongside reliable supply, Zuellig Pharma is committed to supporting healthcare professionals and patients through education and trusted information, helping people navigate healthcare services and make informed decisions with their healthcare providers.
Reliable access depends on how a medicine is handled and supplied. Zuellig Pharma works with healthcare partners to support appropriate storage, dependable delivery and accurate product information, helping them provide ongoing care for people living with chronic conditions.
The introduction of Original r-DNA Semaglutide adds a treatment option to Cambodia’s response to type 2 diabetes. By combining responsible distribution with education and support for informed prescribing, Zuellig Pharma aims to strengthen patient-centered care and contribute to better long-term health outcomes for communities across Cambodia.
About Zuellig Pharma:
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multi-billion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
For more information, visit: https://www.zuelligpharma.com/